PMA device
Implantable System for Remodulin
Medtronic, Inc. · Pump, Infusion, Implanted, Programmable (LKK, Class III) · First FDA decision Apr 17, 2018, newest Aug 31, 2021Chronic pain
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
7
Naming "Remodulin"
MAUDE reports
483
Brand "Remodulin", since 2015
PubMed studies
30
Mentioning "Remodulin"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Implantable System for Remodulin
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- Implantable System for RemodulinPMA supplement
P140032-S074 · Decided Aug 31, 2021 · 27 days after receipt · Normal 180 Day Track No User Fee
Device type: Pump, infusion, implanted, programmable (LKK) · Hospital Medicine & Nursing
- Implantable System for Remodulin (ISR)PMA supplement
P140032-S058 · Decided Jan 15, 2021 · 179 days after receipt · Normal 180 Day Track
Device type: Pump, infusion, implanted, programmable (LKK) · Hospital Medicine & Nursing
- Implantable System for RemodulinPMA supplement
P140032-S047 · Decided Oct 21, 2020 · 303 days after receipt · Normal 180 Day Track
Device type: Pump, infusion, implanted, programmable (LKK) · Hospital Medicine & Nursing
3 more FDA decisions with a free account
Older decisions: P140032-S001
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Remodulin", any status and sponsor, newest update first.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseEnrolling by invitation
United TherapeuticsNot on our public-company list
NCT04905693 · 1,850 participants (planned) · Start Sep 6, 2022 · Primary completion Dec 2029
Device: Treprostinil Ultrasonic Nebulizer · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Franklin, Arizona; Phoenix, Arizona · 192 sites in all
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsNot on our public-company list
NCT05255991 · 597 participants · Start Sep 12, 2022 · Primary completion Jun 30, 2025
Device: Treprostinil Ultrasonic Nebulizer · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Mar del Plata, Argentina; Córdoba, Argentina · 108 sites in all
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Pivotal-lookingRecruiting
United TherapeuticsNot on our public-company list
NCT05943535 · 698 participants (planned) · Start Oct 30, 2023 · Primary completion Nov 2027
Device: Treprostinil Ultrasonic Nebulizer · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 165 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Remodulin", and for the whole product code for context.
This brand
483 reports: 408 malfunction, 66 injury, 9 death
Whole product code LKK
71,356 reports: 25,333 malfunction, 45,674 injury, 326 death
Newest reports for this brand
Millyard Advanced Medical Products, LLC
3016798778-2026-00830 · Received Oct 29, 2026 · Event dated Sep 28, 2026
Device type: Pump, Infusion (FRN)
Device problem as coded: Failure to Power Up; Wireless Communication Problem
Patient problem as coded: Anxiety
Millyard Advanced Medical Products, LLC
3016798778-2026-00821 · Received Oct 28, 2026 · Event dated Sep 27, 2026
Device type: Pump, Infusion (FRN)
Device problem as coded: Failure to Pump; No Audible Prompt/Feedback; Wireless Communication Problem
Patient problem as coded: Insufficient Information
Millyard Advanced Medical Products, LLC
3016798778-2026-00792 · Received Oct 23, 2026 · Event dated Apr 27, 2026
Device type: Infusion Pump, Drug Specific, Pharmacy-Filled (QJY)
Device problem as coded: Intermittent Infusion
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Remodulin"[tiab]. The summary above synthesizes these.
- Sotatercept (Winrevair) for pulmonary arterial hypertension.
Med Lett Drugs Ther · 2024
- Treprostinil for pulmonary hypertension.
Vachiéry JL, Naeije R · Expert Rev Cardiovasc Ther · 2004Review
- Treprostinil sodium Pharmacia.
Chattaraj SC · Curr Opin Investig Drugs · 2002Review
- Remodulin® Pump Failure: An Emergency Medicine Simulation Scenario.
Wipprecht S, Wagner J, Bona A, et al. · Cureus · 2020
- A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
Kumar P, Thudium E, Laliberte K, et al. · Clin Pharmacokinet · 2016Review, Research Support, Non-U.S. Gov't
- Treprostinil (Remodulin) for pulmonary arterial hypertension.
Med Lett Drugs Ther · 2002
- Implantable system for treprostinil: a real-world patient experience study.
Shapiro S, Bourge RC, Pozella P, et al. · Pulm Circ · 2020
- Oral treprostinil for the treatment of pulmonary arterial hypertension.
de Lartigue J · Drugs Today (Barc) · 2014
- Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension.
LaRoy V, Roberts E, Mayeux J, et al. · Adv Ther · 2026Review, Research Support, Non-U.S. Gov't
- Patient safety challenges in treprostinil therapy.
Roncesvalles A, Lee FW, Camamo J, et al. · Medsurg Nurs · 2008Review
- Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report.
Mohan N, Dalip D, Jaggernauth S · Cureus · 2022Case Reports
Other devices of this type
Also filed under product code LKK.
- SynchroMed Infusion System, Ascenda Intrathecal CathetersMedtronic, Inc. · PMA 2026
- Prometra Programmable Infusion Pump SystemInfusyn Therapeutics, LLC · PMA 2025
- Synchromed II Pump RemediationMedtronic, Inc. · PMA 2017
- Medstream Programmable Infusion SystemIntera Oncology · PMA 2014
- IsoMed Infusion SystemMedtronic, Inc. · PMA 2023
- INFUSAID Implantable Infusion Pump and AccessoriesIntera Oncology · PMA 2020
- Medtronic(R) Synchromed(Tm) Pump & Infusion SystemMedtronic, Inc. · PMA 2018
- 3000 Series Implantable Infusion Pump and the MedStream Programmable Infusion System and AccessoriesIntera Oncology · PMA 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.